COMPLIANCE An Observational Study of Treatment Compliance and Quality of Life in Patients on Antihypertensive Medication
1 other identifier
observational
1,501
0 countries
N/A
Brief Summary
The aim of this multi-centre survey is to assess treatment adherence and quality of life in a Jordanian and Lebanese population newly diagnosed with hypertension or with uncontrolled essential hypertension being on antihypertensive treatment for at least 6 months.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2011
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
January 10, 2011
CompletedFirst Posted
Study publicly available on registry
January 11, 2011
CompletedStudy Start
First participant enrolled
May 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2012
CompletedSeptember 11, 2013
September 1, 2013
1.3 years
January 10, 2011
September 10, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Compliance rate
Identify the percentage of subjects compliant to their antihypertensive treatment.
6 months
Secondary Outcomes (5)
Health Related Quality of Life (MINICHAL Score)
6 months
Type of pharmacological treatments
6 months
Factors affecting adherence to treatment
6 months
Compliance rate by antihypertensive regimen used
6 months
Percentage of controlled patients
6 months
Eligibility Criteria
multi-centre survey of patients
You may qualify if:
- Patients older than 21 years of age
- Patients newly diagnosis with essential hypertension or with hypertension that is uncontrolled after being under the same antihypertensive treatment for at least 6 months (based on the criteria established by the Joint National Committee VII)
- Patients capable of providing an informed consent
You may not qualify if:
- Patients with secondary hypertension
- Pregnant women or nursing mothers
- Patients with acute illnesses or psychiatric diagnosis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- AstraZenecalead
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 10, 2011
First Posted
January 11, 2011
Study Start
May 1, 2011
Primary Completion
September 1, 2012
Study Completion
September 1, 2012
Last Updated
September 11, 2013
Record last verified: 2013-09